Contrast-induced acute kidney injury: Specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology

Mayo Clinic Proceedings

Volumn 84, Issue 2, 2009, Pages 170-179

  Goldfarb, Stanley ^a   McCullough, Peter A ^b   McDermott, John ^c   Gay, Spencer B ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c University of Wisconsin Health   (United States)

^d UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; BICARBONATE; CONTRAST MEDIUM; IODIXANOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOXAGLIC ACID; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; SODIUM CHLORIDE; CREATININE; SCAVENGER;

CARDIOLOGIST; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CONTRAST INDUCED NEPHROPATHY; DIAGNOSTIC PROCEDURE; HOSPITAL PATIENT; HUMAN; INCIDENCE; INTERNET; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; INTERVENTIONAL RADIOLOGY; MEDLINE; NEPHROLOGIST; OUTPATIENT; RADIOLOGIST; REVIEW; RISK ASSESSMENT; SCREENING; ACUTE KIDNEY FAILURE; BLOOD; CHEMICALLY INDUCED DISORDER; GLOMERULUS FILTRATION RATE; MEDICINE; PRACTICE GUIDELINE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACETYLCYSTEINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL PROTOCOLS; CONTRAST MEDIA; CREATININE; FREE RADICAL SCAVENGERS; GLOMERULAR FILTRATION RATE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RADIOGRAPHY, INTERVENTIONAL; RENAL INSUFFICIENCY, ACUTE; RISK ASSESSMENT; SPECIALTIES, MEDICAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 61449236337     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.2.170     Document Type: Review

References (73)

1. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
2. Molitoris BA, Levin A, Warnock DG, et al; Acute Kidney Injury Network Working Group. Improving outcomes of acute kidney injury: report of an initiative. Nat Clin Pract Nephrol. 2007;3(8):439-442.
3. Morcos SK. Contrast medium-induced nephrotoxicity. In: Dawson P, Cosgrove DO, Grainger RG, eds. Textbook of Contrast Media. Oxford, England: Isis Medical Media Ltd; 1999:135-148.
4. Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med. 2003;4(suppl 1):S7-S14.
5. McCullough PA, Adam A, Becker CR, et al; CIN Consensus Working Panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006 Sep 16;98(6A):5K-13K. Epub 2006 Feb 10.
6. McCullough PA. Multimodality prevention of contrast-induced acute kidney injury. Am J Kidney Dis. 2008;51(2):169-172.
7. Brosius FC III, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group developed in collaboration with the National Kidney Foundation. Circulation. 2006 Sep 5;114(10):1083-1087. Epub 2006 Aug 7.
8. Rudnick MR, Goldfarb S, Wexler L, et al; Iohexol Cooperative Study. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int. 1995;47(1):254-261.
9. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-2264.
10. McCullough PA, Adam A, Becker CR, et al; CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006 Sep 18;98(6A):27K-36K. Epub 2006 Feb 23.
11. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med. 1990;89(5):615-620.
12. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368-375.
13. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36(5):1542-1548.
14. Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006 Oct;17(10):2871-2877. Epub 2006 Aug 23.
15. Hassoun HT, Grigoryev DN, Lie ML, et al. Ischemic acute kidney injury induces a distant organ functional and genomic response distinguishable from bilateral nephrectomy. Am J Physiol Renal Physiol. 2007 Jul;293(1):F30-F40. Epub 2007 Feb 27.
16. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee [published correction appears in Circulation. 2008;117(6):e161]. Circulation. 2008 Jan 15;117(2):261-295. Epub 2007 Dec 13.
17. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons; endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):652-726.
18. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006 Sep 5;48(5):924-930. Epub 2006 Aug 17.
19. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared to low-osmolar contrast media. J Am Coll Cardiol. 2006 Aug 16;48(4):692-699. Epub 2006 Jul 24.
20. Segal A, Ellis JH, Baumgartner BR, et al. Manual on Contrast Media: Version 6; 2008. ACR Am Coll Radiol. http://www.acr.org/ SecondaryMainMenuCategories/quality-safety/contrast-manual.aspx. Accessed December 23, 2008.
21. National Kidney Foundation DOQI. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. http://www.kidney.org/ professionals/KDOQI/guidelines-cvd/guide2.htm. Accessed December 23, 2008.
22. European Society of Urogenital Radiology. ESUR Guidelines on Contrast Media, Version 6.0. http://www.esur.org/ESUR-Guidelines-NEW.6.0 .html. Accessed December 23, 2008.
23. Holder JC, Dalrymple GV. Pain and aortofemoral arteriography: the importance of chemical structure and osmolality of contrast agents. Invest Radiol. 1981;16(6):508-512.
24. Manke C, Marcus C, Page A, Puey J, Batakis O, Fog A. Pain in femoral arteriography: a double-blind, randomized, clinical study comparing safety and efficacy of the iso-osmolar iodixanol 270 mgI/ml and the low-osmolar iomeprol 300 mgI/ml in 9 European centers. Acta Radiol. 2003;44(6):590-596.
25. Kløw NE, Levorstad K, Berg KJ, et al. Iodixanol in cardioangiography in patients with coronary artery disease: tolerability, cardiac and renal effects. Acta Radiol. 1993;34(1):72-77.
26. Tveit K, Bolz KD, Bolstad B, et al. Iodixanol in cardioangiography: a double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml. Acta Radiol. 1994;35(6):614-618.
27. Palmers Y, De Greef D, Grynne BH, Smits J, Put E. A double-blind study comparing safety, tolerability and efficacy of iodixanol 320 mgI/ml and ioxaglate 320 mgI/ml in cerebral arteriography. Eur J Radiol. 1993;17(3):203-209.
28. Pugh ND, Sissons GR, Ruttley MS, Berg KJ, Nossen JO, Eide H. Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide. Clin Radiol. 1993;47(2):96-99.
29. Verow P, Nossen JO, Sheppick A, Kjaersgaard P. A comparison of iodixanol with iopamidol in aorto-femoral angiography. Br J Radiol. 1995;68(813):973-978.
30. Justesen P, Downes M, Grynne BH, Lang H, Rasch W, Seim E. Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide. Cardiovasc Intervent Radiol. 1997;20(4):251-256.
31. Thomsen HS. How to avoid CIN: guidelines from the European Society of Urogenital Radiology. Nephrol Dial Transplant. 2005;20(suppl 1):i18-i22.
32. Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech Urol. 1998;4(2):65-69.
33. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-1399.
34. Band RA, Gaieski DF, Mills AM, et al. Discordance between serum creatinine and creatinine clearance for identification of ED patients with abdominal pain at risk for contrast-induced nephropathy. Am J Emerg Med. 2007;25(3):268-272.
35. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461-470.
36. Lameire N, Adam A, Becker CR, et al; CIN Consensus Working Panel. Baseline renal function screening. Am J Cardiol. 2006 Sep 18;98(6A):21K-26K. Epub 2006 Feb 20.
37. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005 Mar;16(3):763-773. Epub 2005 Jan 19.
38. Rigalleau V, Lasseur C, Perlemoine C, et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or Modification of Diet in Renal Disease study equation? Diabetes Care. 2005;28(4):838-843.
39. Beauvieux MC, Le Moigne F, Lasseur C, et al. New predictive equations improve monitoring of kidney function in patients with diabetes. Diabetes Care. 2007 Aug;30(8):1988-1994. Epub 2007 May 29.
40. Firestone D, Wos A, Killeen JP, et al. Can urine dipstick be used as a surrogate for serum creatinine in emergency department patients who undergo contrast studies? J Emerg Med. 2007 Aug;33(2):119-122. Epub 2007 Jun 13.
41. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med. 2003;4(suppl 5):S3-S9.
42. O'Hare AM, Bertenthal D, Covinsky KE, et al. Mortality risk stratification in chronic kidney disease: one size for all ages? J Am Soc Nephrol. 2006 Mar;17(3):846-853. Epub 2006 Feb 1.
43. Stacul F, Adam A, Becker C, et al; CIN Consensus Working Panel. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006 Sep 18;98(6A):59K-77K. Epub 2006 Mar 20.
44. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol. 2004;62(1):1-7.
45. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93(1):C29-C34.
46. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162(3):329-336.
47. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328-2334.
48. Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol. 2007 Sep 1;100(5):781-786. Epub 2007 Jun 13.
49. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007 Mar 13;115(10):1211-1217. Epub 2007 Feb 19.
50. Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO study. J Am Coll Cardiol. 2007 Mar 27;49(12):1283-1288. Epub 2007 Mar 12.
51. Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy: a comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures: a single-center prospective controlled trial. Am Heart J. 2007;154(3):539-544.
52. Hogan SE, L'Allier P, Chetcuti S, et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J. 2008;156(3):414-421.
53. From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol. 2008 Jan;3(1):10-18. Epub 2007 Dec 5.
54. Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52(8):599-604.
55. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180-184.
56. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Metaanalysis: effectiveness of drugs for preventing contrast-induced nephropathy [published correction appears in Ann Intern Med. 2008;149(3):219]. Ann Intern Med. 2008;148(4):284-294.
57. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol. 2008 Jan;3(1):281-287. Epub 2007 Nov 14.
58. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004 Nov 2;110(18):2837-2842. Epub 2004 Oct 18.
59. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. Ann Intern Med. 1989;110(2):119-124.
60. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86(6, pt 1):649-652.
61. Freeman RV, O'Donnell M, Share D, et al; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90(10):1068-1073.
62. Laskey WK, Jenkins C, Selzer F, et al; NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearance ratio: pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007 Aug;50(7):584-590. Epub 2007 Jul 30.
63. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188(1):171-178.
64. Feldkamp T, Baumgart D, Elsner M, et al. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol. 2006;66(5):322-330.
65. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ; NEPHRIC Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348(6):491-499.
66. Solomon RJ, Natarajan MK, Doucet S, et al; Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007 Jun 26;115(25):3189-3196. Epub 2007 Jun 11.
67. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006;41(11):815-821.
68. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol. 2008;191(1):151-157.
69. Thomsen HS, Morcos SK, Erley CM, et al; Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and idoixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43(3):170-178.
70. McCullough PA. Contrast-induced acute kidney injury [published correction appears in J Am Coll Cardiol. 2008;51(22):2197]. J Am Coll Cardiol. 2008;51(15):1419-1428.
71. Chertow GM, Normand SL, McNeil BJ. "Renalism": inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol. 2004;15(9):2462-2468.
72. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13-19.
73. Love L, Johnson MS, Bresler ME, Nelson JE, Olson MC, Flisak ME. The persistent computed tomography nephrogram: its significance in the diagnosis of contrast-associated nephrotoxicity. Br J Radiol. 1994;67(802):951-957.